Fulcrum Therapeutics, Inc. (FULC) vs Upstream Bio, Inc. (UPB)
Fulcrum Therapeutics, Inc. and Upstream Bio, Inc. are both Biotechnology companies. Fulcrum Therapeutics, Inc. and Upstream Bio, Inc. are of similar size ($288.8M and $283.2M). Fulcrum Therapeutics, Inc. grew revenue faster over the last twelve months: 1,939.8% against 16.0%. Fulcrum Therapeutics, Inc. has the higher net margin (0.00% vs −4,955.7%) and the higher return on invested capital (0.00% vs −1,100.9%). Across the 15 metrics below, Fulcrum Therapeutics, Inc. leads on 13 and Upstream Bio, Inc. on 2.
Valuation
Profitability
| Metric | FULC | UPB | Biotechnology median |
|---|---|---|---|
| Gross margin | 100.00% | 100.00% | 65.16% |
| Operating margin | 0.00% | (5,382.65%) | 0.00% |
| Net margin | 0.00% | (4,955.67%) | 0.00% |
| Free cash flow margin | 0.00% | (4,317.42%) | 0.00% |
| Return on equity | (32.38%) | (46.05%) | (57.72%) |
| Return on assets | (30.75%) | (44.61%) | (49.22%) |
| Return on invested capital | 0.00% | (1,100.93%) | 0.00% |
Growth
Health
Dividend
Size
Any metric, up to five companies and an Excel export Powerpack